Pirfenidone

(Esbriet®)

Pirfenidone

Drug updated on 11/10/2023

Dosage FormCapsule (oral: 267 mg); Tablet (oral: 267 mg, 801 mg)
Drug ClassPyridones
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of idiopathic pulmonary fibrosis (IPF).

Product Monograph / Prescribing Information

Document TitleYearSource
Esbriet (pirfenidone) Prescribing Information.2022Genentech USA, Inc., South San Francisco, CA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults.2022American Journal of Respiratory and Critical Care Medicine
German guideline for idiopathic pulmonary fibrosis - update on pharmacological therapies 2017.2018Pneumologie (Stuttgart, Germany)